Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence"

Drugs. 2022 Feb;82(3):353-354. doi: 10.1007/s40265-022-01681-8. Epub 2022 Feb 12.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • COVID-19 Drug Treatment*
  • Fluvoxamine*
  • Humans
  • SARS-CoV-2

Substances

  • Fluvoxamine